Zacherl J, Hamilton G, Thalhammer T, Riegler M, Cosentini E P, Ellinger A, Bischof G, Schweitzer M, Teleky B, Koperna T
I. Department of Surgery, University of Vienna, Austria.
Cancer Chemother Pharmacol. 1994;34(2):125-32. doi: 10.1007/BF00685929.
The ability of the multidrug resistance modifiers R- and R,S-verapamil (VPL), cyclosporine A (CsA) and its non-immunosuppressive derivative SDZ PSC 833 (PSC 833) to inhibit P-glycoprotein (P-gp)-mediated transepithelial flux of tritiated vinblastine was investigated using tight and highly resistant (R > 1,400 omega cm2) monolayer cultures of intestinal adenocarcinoma-derived HCT-8 cells grown on permeable tissue-culture inserts. Apical addition of these chemosensitizers inhibited drug flux (137 pmol h-1 cm-2; range, 133-142 pmol h-1 cm-2) in the basal to apical secretory direction at clinically relevant concentrations, with PSC 833 showing the highest activity, exhibiting inhibition at concentrations as low as 10 ng/ml (9 nM). Acidification of the modulator-containing apical compartment to an extracellular pH (pHo) of 6.8 had no influence on MDR reversal by CsA at 1 microgram/ml (0.9 microM; flux inhibition, 52%) or by PSC 833 at 100 ng/ml (0.09 microM; flux inhibition, 60%), in contrast to R,S- and R-VPL, which showed decreased inhibition and caused less accumulation of vinblastine in HCT-8 cells under this condition (flux inhibition of 35% and 23%, respectively, at pHo 6.8 vs 50% and 43%, respectively, at pHo 7.5). P-gp-mediated rhodamine 123 efflux from dye-loaded single-cell suspensions of HCT-8 cells as measured by flow cytometry was not impeded at pHo 6.8 in comparison with pHo 7.5 in standard medium, but at low pHo the inhibitory activity of R-VPL (29% vs 60% rhodamine 123 efflux inhibition) was diminished significantly, again without a reduction in the effect of PSC 833 (rhodamine 123 flux inhibition, 75%). In conclusion, drug extrusion across polarised monolayers, which offer a relevant model for normal epithelia and tumour border areas, is inhibited by the apical presence of R,S- and R-VPL, CsA and PSC 833 at similar concentrations described for single-cell suspensions, resulting in increased (2.2- to 3.7-fold) intracellular drug accumulation. Functional apical P-gp expression, the absence of paracellular leakage and modulator-sensitive rhodamine 123 efflux in single HCT-8 cells indicate a P-gp-mediated transcellular efflux in HCT-8 monolayers. In addition to its high MDR-reversing capacity, the inhibitory activity of PSC 833 is not affected by acidic extracellular conditions, which reduce the VPL-induced drug retention significantly. As far as MDR contributes to the overall cellular drug resistance of solid tumours with hypoxic and acidic microenvironments, PSC 833 holds the greatest promise for clinical reversal of unresponsiveness to the respective group of chemotherapeutics.
使用生长在可渗透组织培养插入物上的肠道腺癌来源的HCT - 8细胞的紧密且高抗性(R>1400Ω·cm²)单层培养物,研究了多药耐药修饰剂R - 维拉帕米(VPL)、R,S - 维拉帕米、环孢素A(CsA)及其非免疫抑制衍生物SDZ PSC 833(PSC 833)抑制P - 糖蛋白(P - gp)介导的氚化长春碱跨上皮转运的能力。在临床相关浓度下,向顶端添加这些化学增敏剂可抑制基底到顶端分泌方向的药物转运(137 pmol·h⁻¹·cm⁻²;范围为133 - 142 pmol·h⁻¹·cm⁻²),其中PSC 833活性最高,在低至10 ng/ml(9 nM)的浓度下即可表现出抑制作用。将含有调节剂的顶端隔室酸化至细胞外pH(pHo)为6.8,对1μg/ml(0.9μM;转运抑制率为52%)的CsA或100 ng/ml(0.09μM;转运抑制率为60%)的PSC 833的多药耐药逆转没有影响,与之形成对比的是,R,S - 和R - VPL在此条件下抑制作用降低,且导致长春碱在HCT - 8细胞中的积累减少(pHo 6.8时转运抑制率分别为35%和23%,而pHo 7.5时分别为50%和43%)。通过流式细胞术测量,与标准培养基中pHo 7.5相比,pHo 6.8时P - gp介导的罗丹明123从负载染料的HCT - 8单细胞悬液中的外排未受阻碍,但在低pHo时,R - VPL的抑制活性显著降低(罗丹明123外排抑制率从60%降至29%),而PSC 833的作用不受影响(罗丹明123转运抑制率为75%)。总之,跨极化单层的药物外排受到R,S - 和R - VPL、CsA和PSC 833顶端存在的抑制,这些物质在与单细胞悬液描述的相似浓度下发挥作用,导致细胞内药物积累增加(2.2至3.7倍)。功能性顶端P - gp表达、单细胞悬液中无细胞旁渗漏以及调节剂敏感的罗丹明123外排表明HCT - 8单层中存在P - gp介导的跨细胞外排。除了具有高多药耐药逆转能力外,PSC 833的抑制活性不受酸性细胞外条件的影响,而酸性条件会显著降低VPL诱导的药物滞留。就多药耐药对具有缺氧和酸性微环境的实体瘤整体细胞耐药性的影响而言,PSC 对于临床逆转对相应化疗药物组的无反应性最具前景。